Chang Yu - Lymphoma Diagnosed & Treatment Ctr Henan Prov, Zhengzhou Univ

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 22 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Trial in Progress: Phase 1 Dose Escalation Study of T-1101, a First-in-class Oral Hec1/Nek2 Inhibitor, in Patients with Advanced Refractory Solid Tumors

Wu-Chou Su,Li-Yuan Bai, Hui-Hua Hsiao, Her-Shyong Shiah, Yu-Min Yeh, Shang-Hung Chen,Shang-Yin Wu, Hui-Ching Wang,Hui-Jen Tsai,Kwang-Yu Chang, Jui-Hung Tsai,Chun-Hui Lee, Chieh Hua Lee, Yu-Sheng Chao, Li-Tzong Chen

CANCER RESEARCHno. 7 (2024)

Cited0Views0Bibtex

Palmitic Acid Reduces the Methylation of the FOXO1 Promoter to Suppress the Development of Diffuse Large B-cell Lymphoma Via Modulating the Mir-429/Dnmt3a Axis

Weiming Li,Ming Gao,Weili Xue,Xiaoli Li,Yu Chang, Kaixin Zhang, Chenyu Wen,Mingzhi Zhang

Chinese Journal of Natural Medicinesno. 6 (2024)

Cited0Views0WOSBibtex

Efficacy and Safety of Chemotherapy (DDGP vs VIPD) Followed Radiotherapy Vs Radiotherapy Followed Chemotherapy (DDGP vs VIPD) Vs Radiotherapy Alone for Newly Diagnosed Early Stage Extranodal Natural Killer/T Cell Lymphoma: Final Results of a Prospective, Multicenter, Randomized, Controlled Clinical Trial

Mingzhi Zhang,Lei Zhang,Xin Li,Ling Li,Xinhua Wang,Xiaorui Fu,Zhenchang Sun,Yu Chang,Xudong Zhang,Hui Yu,Feifei Nan,Zhiyuan Zhou,Xiyang Liu,Xiaolong Wu,Liqun Zou,Hui Zhou,Hongwei Xue

Blood (2023): 1690

Cited0Views0Bibtex

ERCC6L Facilitates the Progression of Laryngeal Squamous Cell Carcinoma by the Binding of FOXM1 and KIF4A

Meng Cui,Yu Chang,Jiheng Wang,Junfu Wu,Gang Li, Jie Tan

Cell Death Discovery（2023）

Cited1Views0WOSNATUREBibtex

ERCC6L facilitates the progression of laryngeal squamous cell carcinoma by the binding of FOXM1 and KIF4A (vol 9, 41, 2023)

Meng Cui,Yu Chang,Jiheng Wang,Junfu Wu, Gang Li, Jie Tan

CELL DEATH DISCOVERYno. 1 (2023)

Cited0Views0Bibtex

Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial

Lei Zhang,Xiyang Liu,Xinhua Wang,Yu Chang,Xiaorui Fu,Xin Li, Ling Li,Jiaqin Yan,Feifei Nan,Xiaolong Wu,Linan Zhu,Zhenchang Sun,Hui Yu,Mingzhi Zhang

BLOOD (2021)

Cited0Views0Bibtex

Author response for "Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system"

Li, Xingying, Yu, Hui, Fu, Xiaorui, Zhang, Lei, Li, Xin, Li, Ling, Wang, Xinhua, Sun, Zhenchang, Zhang, Xudong, Li, Zhaoming, Wu, Jingjing, Chang, Yu, Yan, Jiaqin, Zhou, Zhiyuan, Nan, Feifei, Wu, Xiaolong, Tian, Li, Zhang, Mingzhi

crossref（2021）

Cited0Views0Bibtex

Integrating Circulating Tumor DNA Features and Plasma Protein Markers to Detected Early Lymphoid Neoplasm

Xinhua Wang,Yu Chang,Dandan Zhu,Shiyong Li,Shuaipeng Geng,Yinyin Chang,Yan Chen,Mao Mao,Mingzhi Zhang

Blood（2021）

Cited3Views0Bibtex

Lei Zhang,Xiyang Liu,Xinhua Wang,Yu Chang,Xiaorui Fu,Xin Li, Ling Li,Jiaqin Yan,Feifei Nan,Xiaolong Wu,Linan Zhu,Zhenchang Sun,Hui Yu,Mingzhi Zhang

Blood（2021）

Cited1Views0Bibtex

≪p>efficacy of Dose-Adjusted EPOCH Plus Rituximab/r-Chop Regimens and the Prognosis Analysis in Patients with myc, bcl2/bcl6 Gene Copy Number Gain Lymphoma and Double-Hit Lymphoma: Results from a Single Institution Retrospective Clinical Study

Qianwen Ma,Yu Chang, Ling Li,Xin Li,Xinhua Wang,Jingjing Wu,Xiaorui Fu, Zhihua Sun, Hui Yu,Xudong Zhang,Zhiyuan Zhou,Feifei Nan,Zhaoming Li,Xi-Yang Liu, Qi Zhao, Yang Li,Lan Zhang,Mingzhi Zhang,Lei Zhang

Cancer management and research (2019): 1363-1372

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn